david wolf, md, phd pediatric neurology group 4
DESCRIPTION
Characterization of retinal thickness in children with neurofibromatosis type 1 and optic pathway gliomas using optical coherence tomography. David Wolf, MD, PhD Pediatric Neurology Group 4. Neurofibromatosis Type 1. Autosomal dominant neurocutaneous disorder Incidence of 1:3500 - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/1.jpg)
Characterization of retinal thickness in children with neurofibromatosis type 1 and optic pathway gliomas
using optical coherence tomography
David Wolf, MD, PhDPediatric Neurology
Group 4
![Page 2: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/2.jpg)
Neurofibromatosis Type 1
• Autosomal dominant neurocutaneous disorder
• Incidence of 1:3500
• Diagnosis based primarily on clinical criteria
![Page 3: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/3.jpg)
![Page 4: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/4.jpg)
![Page 5: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/5.jpg)
![Page 6: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/6.jpg)
Optic Pathway Gliomas and NF1• 15% of children with NF1 (Listernick et al, J Pediatr 1994)
• Age <6 years– Can be seen into early adulthood
• Present with:– Diminished visual acuity
• Difficult to assess
– Proptosis– Precocious puberty
• Tumor causes compressive damage to optic nerve
![Page 7: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/7.jpg)
Current Guidelines
• Yearly ophthalmologic exam– Acuity– Visual fields– Color vision
• Follow growth curves closely
• If optic pathway glioma suspected, MRI indicated– No indication for “screening” neuroimaging
![Page 8: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/8.jpg)
Post-contrast
T2 T2
![Page 9: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/9.jpg)
Problems with MRI
• Can follow size, enhancement over time
• Changes not associated with visual acuity
• Requires general anesthesia– May be needed up to 8 times over 2 years
![Page 10: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/10.jpg)
Other testing modalities?
• Noninvasive
• Fast
• Can be performed on children
• Quantitative
• Correlates with standard visual acuity testing
![Page 11: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/11.jpg)
Optical Coherence Tomography
![Page 12: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/12.jpg)
![Page 13: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/13.jpg)
![Page 14: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/14.jpg)
Optical Coherence Tomography
• Noninvasive, no ionizing radiation
• Gives quantitative, reproducible measurement of retinal thickness
• Decreased retinal thickness correlates with poorer visual acuity
• Tumors that compress the optic nerve decrease retinal thickness– OPGs have not been specifically examined
![Page 15: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/15.jpg)
Hypothesis
• Retinal nerve layer thickness will be decreased in children with optic pathway glioma relative to children without optic pathway glioma
• This is a feasibility study. In the future, we hope to use OCT as a tool to follow progression of OPGs
![Page 16: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/16.jpg)
Study design
• Cross sectional study of children seen in the Johns Hopkins Outpatient Center
![Page 17: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/17.jpg)
Inclusion and Exclusion Criteria• Inclusion: Children aged 6-19 years
• Exclusion– History of optic neuritis, papilledema– Chemotherapy for optic glioma– Glioma regression– Foster children– Unable to sit for exam
• Myopia and hyperopia are NOT exclusion criteria
![Page 18: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/18.jpg)
Definition of three comparison groups• Neurofibromatosis Type 1 with OPG– First occurrence of OPG as assessed by MRI– Recruited through referral from neuro-oncology and
neuro-ophthalmology
• Neurofibromatosis Type 1 without OPG– Based on clinical diagnosis– Matched to cases with OPG on age (+/- 3 years)– Recruited through neurofibromatosis clinic
• Non-NF1 controls recruited from general pediatric neurology clinic
![Page 19: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/19.jpg)
Assessment of Retinal Thickness• OCT performed by one
person (me) on one machine
• Complete retinal thickness measured in each eye once
• Average retinal thickness will be used in analysis
![Page 20: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/20.jpg)
Additional Testing
• Visual acuity– Snellen visual acuity testing– Sloan low contrast visual acuity– Will be used for secondary analysis
• Demographic factors, medical history collected at time of exam– Prior imaging studies– Prior ophthalmologic exams
![Page 21: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/21.jpg)
Power calculation
Mean (controls): 100 micronsMean (OPG): 90 micronsSD (controls): 30SD (OPG): 30Alpha: 0.05Power: 0.8
Sample size: 19 subjects per group
![Page 22: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/22.jpg)
Analytical Plan• ANOVA comparing retinal thickness between
three groups
• General linear regression to compare differences in retinal thickness between all three groups (using non-NF1 as reference group) while adjusting for age, sex, and other potential confounders
• Correlation matrix of retinal thickness, visual acuity, and tumor size
![Page 23: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/23.jpg)
Power calculation
Mean (controls): 100 micronsMean (OPG): 90 micronsSD (controls): 30SD (OPG): 30Alpha: 0.05Power: 0.8
Sample size: 19 subjects per group
![Page 24: David Wolf, MD, PhD Pediatric Neurology Group 4](https://reader036.vdocument.in/reader036/viewer/2022062501/56815e09550346895dcc6316/html5/thumbnails/24.jpg)
Significance
• Children with OPGs require frequent MR imaging to monitor tumor progression– In young children requires general anesthesia
• OCT can serve as non-invasive method to follow OPG and assess progression of tumor